Sequana Medical NV has announced the US FDA approval of its Alfapump system for treating recurrent or refractory ascites due to liver cirrhosis. This approval marks Alfapump as the first active ...

Sequana Medical NV received premarket approval from the U.S. FDA for its Alfapump system to treat recurrent or refractory ascites due to liver cirrhosis. Data from the Poseidon pivotal study showed ...

Ghent, Belgium – 23 December 2024 – Sequana Medical NV (Euronext Brussels: SEQUA, the "Company" or "Sequana Medical") , a pioneer in the treatment of drug-resistant fluid overload in liver ...

alfapump® is the first US approved active implantable medical device (Class III) for the treatment of recurrent or refractory ascites due to liver cirrhosis US market opportunity estimated at over $2 ...

The US Food and Drug Administration (FDA) has approved Sequana Medical’s alfapump for the treatment of recurrent or refractory ascites due to liver cirrhosis. The agency’s greenlight makes ...

Sequana Medical Announces US FDA Approval of alfapump® for the Treatment of Recurrent or Refractory Ascites due to Liver Cirrhosis The Company will be hosting a further webcast with key opinion ...

Ghent, Belgium – 20 December 2024 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of fluid overload in liver disease, heart failure and ...